Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfanilamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.77 |
| ▸ | CA9 | Q16790 | 12/20 | 0.77 |
| ▸ | CA1 | P00915 | 12/20 | 0.77 |
| ▸ | CA12 | O43570 | 11/20 | 0.77 |
| ▸ | CA7 | P43166 | 8/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.77 |
| ▸ | CA6 | P23280 | 3/20 | 0.77 |
| ▸ | CA5A | P35218 | 3/20 | 0.77 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.77 |
| ▸ | CA4 | P22748 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfanilamide SCHEMBL27635251 | 0.90 | CA2 (0.68) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL419065 | 0.89 | CA2 (0.74) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL4188099 | 0.88 | CA2 (0.90) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL2798899 | 0.88 | CA2 (1.00) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL740 | 0.88 | CA2 (1.00) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL31544839 | 0.88 | CA2 (1.00) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL30659052 | 0.88 | CA2 (1.00) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL737140 | 0.87 | CA2 (0.71) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL28201481 | 0.86 | CA2 (0.85) | CA2CA9CA1CA12CA7 | |
| Sulfanilamide SCHEMBL27364276 | 0.86 | CA2 (0.85) | CA2CA9CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11950480-B2 | Color correction filter for white organic electroluminescent light source, and organic electroluminescent display device | FUJIFILM CORPORATION (JP) | 2024-04-02 | — | — | US | disclosed |
| US-20210005673-A1 | COLOR CORRECTION FILTER FOR WHITE ORGANIC ELECTROLUMINESCENT LIGHT SOURCE, AND ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2021-01-07 | — | — | US | disclosed |
| CN-107995910-A | The inhibitor of human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-05-04 | — | — | CN | disclosed |
| EP-1745032-B1 | CXCR1 and CXCR2 chemokine antagonists | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101605728-B | Systems and methods for removing fluorine-containing compounds from water | 3M INNOVATIVE PROPERTIES CO | 2013-07-24 | — | — | CN | disclosed |
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| CN-101605728-A | Systems and methods for removing fluorine-containing compounds from water | 3M INNOVATIVE PROPERTIES CO (US) | 2009-12-16 | — | — | CN | disclosed |
| US-7326729-B2 | CXCR1 and CXCR2 chemokine antagonists | SCHERING CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| EP-0821670-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | Novartis AG (CH) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | disclosed |
| EP-0351603-B1 | Transvinylation reaction | UNION CARBIDE CORP (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5155253-A | Reacting vinyl derivative of first Bronsted acid with labile Bronsted acid in presence of ruthenium catalyst, maintaining concentration below certain level and removing product as formed | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0506070-A2 | Transvinylation process for the preparation of thermally labile vinyl compounds and vinyl compounds prepared from thermally labile acids | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4981973-A | BRONSTED ACID, RUTHENIUM CATALYST | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0351603-A2 | Transvinylation reaction | UNION CARBIDE CORPORATION (US) | 1990-01-24 | — | — | EP | disclosed |
| CN-86102681-A | The preparation method of p-aminophenol derivative and purposes | — | 1987-10-28 | — | — | CN | disclosed |
| US-4220630-A | ORGANIC SULFONIC ACID DEFOAMER | OCCIDENTAL PETROLEUM CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| US-4196172-A | FROM PHOSPHATE ROCK AND SULFURIC ACID | OCCIDENTAL PETROLEUM CORPORATION (US) | 1980-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | GRIK5, GABRE, GRIK2 | CA2 1400/4885CA9 4017/4885CA1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.